6533b82efe1ef96bd129284b
RESEARCH PRODUCT
Temozolomide (TMZ) in radio-chemotherapy combined schedule for treatment of newly-diagnosed high-grade gliomas (HGG)
G. CompostoP. MontemaggiG. MortellaroP. GuerrieriSergio RizzoS. RussoDario PiazzaIgnazio Carrecasubject
OncologyCancer Researchmedicine.medical_specialtyScheduleTemozolomideSettore MED/06 - Oncologia Medicabusiness.industryNewly diagnosedSurgerySafety profileOncologyInternal medicinemedicinebusinessmedicine.drugRadio chemotherapydescription
1578 Background: Temozolomide (TMZ) is an oral alkylating agent known to cross the blood-brain barrier with efficacy against HGG and a favourable safety profile compared to conventional chemotherap...
year | journal | country | edition | language |
---|---|---|---|---|
2005-06-01 | Journal of Clinical Oncology |